Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
Journal Title
Frontiers in Oncology
Publication Type
Review
Abstract
Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or </=5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT.
Keywords
Psma pet; metastastases directed therapy; metastatic disease; oligometastatic; prostate cancer
Department(s)
Radiation Oncology
PubMed ID
36059632
Open Access at Publisher's Site
https://doi.org/10.3389/fonc.2022.929444
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-25 04:53:40
Last Modified: 2024-09-25 05:00:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙